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OBJECTIVE—Metformin is actively transported into the liver
by the organic cation transporter (OCT)1 (encoded by
SLC22A1). In 12 normoglycemic individuals, reduced-function
variants in SLC22A1 were shown to decrease the ability of
metformin to reduce glucose excursion in response to oral
glucose. We assessed the effect of two common loss-of-function
polymorphisms in SLC22A1 on metformin response in a large
cohort of patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS—The Diabetes Audit
and Research in Tayside Scotland (DARTS) database includes
prescribing and biochemistry information and clinical pheno-
types of all patients with diabetes within Tayside, Scotland, from
1992 onwards. R61C and 420del variants of SLC22A1 were
genotyped in 3,450 patients with type 2 diabetes who were
incident users of metformin. We assessed metformin response by
modeling the maximum A1C reduction in 18 months after start-
ing metformin and investigated whether a treatment target of
A1C 7% was achieved. Sustained metformin effect on A1C
between 6 and 42 months was also assessed, as was the time to
metformin monotherapy failure. Covariates were SLC22A1 ge-
notype, BMI, average drug dose, adherence, and creatinine
clearance.
RESULTS—A total of 1,531 patients were identiﬁed with a
deﬁnable metformin response. R61C and 420del variants did not
affect the initial A1C reduction (P  0.47 and P  0.92, respec-
tively), the chance of achieving a treatment target (P  0.83 and
P  0.36), the average A1C on monotherapy up to 42 months
(P  0.44 and P  0.75), or the hazard of monotherapy failure
(P  0.85 and P  0.56).
CONCLUSIONS—The SLC22A1 loss-of-function variants, R61C
and 420del, do not attenuate the A1C reduction achieved by
metformin in patients with type 2 diabetes. Diabetes 58:1434–
1439, 2009
M
etformin is recommended as ﬁrst-line oral
treatment in the joint American Diabetes As-
sociation (ADA)/European Association for
the Study of Diabetes (EASD) guidelines on
the treatment of type 2 diabetes (1) and has been shown to
be effective in decreasing both micro- and macrovascular
disease (2). The glycemic response to metformin is vari-
able, with some people having a marked response and
others gaining no beneﬁt. Furthermore, between 5 and 10%
of patients are unable to tolerate metformin as a result of
gastrointestinal side effects (3). This variation in met-
formin response may reﬂect phenotypic differences and
variation in drug action or drug distribution. We and
others have shown little or no clinical effect of basic
phenotypic parameters such as age, sex, or BMI on met-
formin response (4–6), suggesting that genetic variation in
pharmacokinetics or pharmacodynamics of metformin at
the molecular level may be important.
Pharmacokinetic studies suggest that metformin, an
organic cation, is actively absorbed from the gut and is
excreted unchanged in the urine. Recent studies have
shown that metformin is actively transported into the liver
by organic cation transporter (OCT)1 (encoded by
SLC22A1) (7,8) and into the renal tubules by OCT2
(encoded by SLC22A2) (9). In a previous study, Shu et al.
(10) show, in mice lacking Slc22a1, that this transporter is
necessary for metformin transport into the liver and for
metformin to elicit its therapeutic effect. In addition, they
describe reduced-function SLC22A1 polymorphisms in
humans that impair the glucose-lowering effect of metformin
during an oral glucose tolerance test. We hypothesized that
two common reduced-function polymorphisms in SLC22A1
(420del and R61C) (10) would decrease glycemic response to
metformin in patients with type 2 diabetes. In the current
study, we assessed a series of drug-response models to
metformin including short- and mid-term A1C reduction,
reaching the treatment target of A1C 7%, and time to
monotherapy failure in a large population-based study of
1,531 subjects residing in Tayside, Scotland.
RESEARCH DESIGN AND METHODS
Patients were selected from an ongoing study of the Genetics of Diabetes
Audit and Research in Tayside Scotland (GoDARTS). (Additional information
is available in an online appendix [http://diabetes.diabetesjournals.org/cgi/
content/full/db08-0896/DC1].) All incident users of metformin (n  3,450)
were included to identify patients informative for the current study following
the ascertainment process outlined in Fig. 1. Two study groups were deﬁned,
each of which required complete data with respect to sex, age, metformin
dose, adherence, and A1C response. The subjects in group 1 received no
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1434 DIABETES, VOL. 58, JUNE 2009diabetes-related drug treatment for at least 6 months before their index
metformin prescription and were thus considered treatment naive. The
subjects in group 2 were stably treated with oral hypoglycemic agents for at
least 6 months before starting metformin and until at least the A1C on
metformin therapy was measured. Both groups required at least 6 months of
metformin use. The study was approved by the Tayside Medical Ethics
Committee, and informed consent was obtained from all subjects.
Models of drug response
Initial A1C reduction. Linear regression was used to model two quantitative
A1C reduction measurements derived from different treatment A1C deﬁni-
tions: 1) the minimum A1C recorded from baseline to 18 months after the
index prescription while the patient was on stable treatment (no additional
therapy initiated or metformin stopped) and 2) the average A1C reﬂecting the
area under the curve of A1C within the same period. The corresponding A1C
reduction was deﬁned as the difference between the baseline and treatment
A1C. The baseline A1C was taken as the nearest A1C within the 180 days
before the index metformin prescription.
Treatment target A1C <7%. Logistic regression was used to model the
ability of patients to reach a treatment target of A1C 7% within 18 months
after the start of metformin given their baseline A1C 7%.
Sustained A1C response. In prospective trials of metformin monotherapy
(e.g., A Diabetes Outcome Progression Trial [ADOPT]) (11) following the
N=3,450
Genotype, Sex, DOB, 
age
R61C 420Del
W/W 87.9% 64.6%
M/M 0.3% 3.5%
W/M 11.7% 31.9%
Stop Metformin  or start additional
Therapy within 180 days
N=654
R61C 420Del
W/W 88.7% 65.6%
M/M 0.2% 4.0%
W/M 11.2% 30.4%
N=2,796
R61C 420Del
W/W 87.8% 64.4%
M/M 0.4% 3.4%
W/M 11.9% 32.2%
No HbA1c recorded 
within 6 months before
starting metformin N=635
No HbA1c recorded between 
6 months and 18 months after
starting metformin N=438
N=1,723
R61C 420Del
W/W 87.5% 64.7%
M/M 0.5% 3.3%
W/M 12.0% 32.0%
Group 1. N=1,014
Drug Naïve before metformin
R61C 420Del
W/W 87.2% 63.2%
M/M 0.4% 3.6%
W/M 12.4% 33.1%
Group 2. N=517
Stably treated with other oral 
agents before and after metformin
R61C 420Del
W/W 87.6% 65.2%
M/M 0.8% 2.5%
W/M 11.6% 32.3%
N=192
R61C 420Del
W/W 89.6% 68.2%
M/M 0.5% 4.7%
W/M 9.9% 27.1%
Not stably treated 
prior to or following 
metformin treatment 
or insulin treated
FIG. 1. Flowchart of patients’ ascertainment. In the mini genotype frequency tables, W/W denotes the wild-type homozygote, M/M denotes the rare
homozygote of CC and Del/Del for R61C and 420del, respectively, and W/M denotes heterozygote. DOB, date of birth.
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DIABETES, VOL. 58, JUNE 2009 1435initial response for 6 months, there was a gradual deterioration in glycemic
control as diabetes progressed. The rate of deterioration of A1C will also
reﬂect the patients’ ability to consistently respond to metformin treatment. In
the current study, we identiﬁed patients on metformin monotherapy for more
than 3.5 years and performed unbalanced repeated-measurement analysis on
their A1C, measured between 6 and 42 months.
Time to monotherapy failure or reaching a dose of 2 g/day. In our
observational study, the primary care physicians will increase the prescribed
metformin dose over time to achieve the treatment target or maintain the A1C
level. Therefore, the time to reach a metformin monotherapy dose of 2 g/day
will provide an additional measure of drug response. Similarly, the time to
start additional therapy (monotherapy failure) will also reﬂect metformin
efﬁcacy. In the current study, we used Cox regression to model time to
metformin monotherapy failure and time to a composite event of either
reaching a 2 g/day dose of metformin or monotherapy failure. For both
analyses, individuals were censored at study end or after 5 years of metformin
monotherapy.
Covariates. In the models of initial drug response, apart from the genetic
factors, the following covariates were included: baseline A1C, average pre-
scribed dose, average adherence, creatinine clearance, BMI, and the study
group (deﬁned in Fig. 1), if applicable. In the repeated-measures analysis, the
dose used was the dose in the 3 months preceding each A1C measure; other
covariates were as per the initial drug response. For the Cox regression
models, baseline A1C, average adherence, creatinine clearance, and genotype
were used as covariates. For the deﬁnition of these covariates, please see the
online appendix.
Genotyping. We genotyped R61C (rs12208357) and 420del variants of
SLC22A1 by Taqman-based allelic discrimination (see the online appendix for
primer and probe sequences and quality-control data). The minor allele
frequencies were 6.7% for R61C and 19.8% for 420del. The R61C mutant only
occurred on the wild-type allele at codon 420. Both variants were in
Hardy-Weinberg equilibrium (P  0.05).
Statistical analysis. Allele frequencies of the two variants were compared
between each subgroup and the original sample in Fig. 1, with a 2 d.f. 
2 test.
Both linear regression analysis of A1C reduction and logistic regression
analysis of achieving treatment target A1C were carried out in PLINK under an
additive model with all the covariates included (http://pngu.mgh.harvard.edu/
purcell/plink/) (12). For the unbalanced repeated-measurement analysis of
A1C between 6 and 42 months, the SAS (version 9.1) Proc Mixed module was
used with covariates of baseline A1C, time of the measurement, the average
dose in the 3 months before each measurement, an additive genetic effect, and
a gene-by-time interaction term. The Cox proportional hazards regression
analysis of time to monotherapy failure was conducted with the survival
package in the statistical software R 2.8.0 (http://www.r-project.org), again
including all of the covariates with the additive genetic model.
RESULTS
As shown in the sample ascertainment ﬂowchart of Fig. 1,
from the initial 3,450 patients we were able to identify
1,531 informative patients for the current study, of whom
1,014 were treatment naive (group 1). Patients were ex-
cluded for the following reasons: 654 patients did not
complete 6 months of metformin treatment, 1,083 patients
did not have sufﬁcient A1C measurements, and 192 pa-
tients could not be classiﬁed into either study group. The
genotype frequencies in any excluded subgroup never
differed signiﬁcantly from the two study groups or the
initial cohort, suggesting that the two variants have no
inﬂuence on metformin intolerance–caused withdrawal or
ascertainment bias.
Baseline characteristics of the patients in study groups 1
and 2 are provided in Table 1. In keeping with the fact that
the patients in group 2 were primarily treated with sulfo-
nylureas, they formed a slimmer cohort with a longer
duration of diabetes. There was no signiﬁcant difference in
these baseline parameters by R61C or 420del genotype.
In the linear regression model (Table 2) of the minimum
treatment A1C achieved, the A1C reduction was indepen-
dently associated with the baseline A1C, creatinine clear-
ance, and metformin adherence. The subjects in group 2
responded less well than those in group 1, in keeping with
their longer duration of diabetes. BMI was not included in
the ﬁnal model because it was not associated with the
response and its inclusion had no effect on the other
measures. In this model, neither the 420del nor the R61C
genotype of SLC22A1 was associated with metformin
response (P  0.47 and P  0.92, respectively). Similar
results were seen even when both study groups were
analyzed separately (data not shown). The alternative
linear regression model of the average A1C reduction still
shows no association between the genotypes and drug
response (supplementary Table A1).
Table 3 shows results of the logistic regression analysis,
which again suggest that neither the 420del nor the R61C
variant has a signiﬁcant effect on metformin response.
However, when the treatment-naive group was analyzed
alone, the R61C genotype, but not the 420del, was associ-
ated with metformin response (odds ratio 1.56; P  0.036),
which suggests that carriers of the loss-of-function C-allele
have a greater likelihood of treatment success.
To further investigate whether the two variants have any
cumulative effect, we combined the genotypes of the two
TABLE 1
Baseline characteristics of the two study groups
Group 1 Group 2
P N Mean SD N Mean SD
Male sex (%) 1,014 52.7 — 517 62.9 — 0.0001
Age diagnosed (years) 1,014 57.1 10.7 517 58.3 9.66 0.02
Age treated with metformin (years) 1,014 59.1 11.2 517 63.1 10.5 0.0001
BMI (kg/m
2) 990 32.5 5.7 509 29.5 4.9 0.0001
Baseline A1C (%) 1,014 8.6 1.6 517 9.2 1.4 0.0001
Average dose (g) 1,014 1.24 0.4 517 1.28 0.4 0.08
Adherence (%) 1,014 75.9 18.0 517 77.9 16.7 0.06
Creatinine clearance (ml/min) 983 97.7 34.0 493 83.9 30.0 0.0001
TABLE 2
Linear regression model of maximum A1C reduction
420del R61C
Coefﬁcient P Coefﬁcient P
Genotype 0.034 0.470 0.007 0.919
Baseline A1C 0.743 0.0001 0.743 0.0001
Creatinine clearance 0.175 0.025 0.175 0.025
Average dose 0.004 0.595 0.004 0.582
Adherence 0.081 0.0001 0.081 0.0001
Group 0.314 0.0001 0.315 0.0001
The coefﬁcients are for the average dose per 100 mg, for creatinine
clearance per 100 ml/min, and for adherence per 10% change. The
genotypes were coded as the dosage of mutant alleles.
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manner (0, no mutant allele at either site; 1, one mutant
allele at either site; and 2, a sum of two or more mutant
alleles at the two sites). When the compound genotypes
were tested in the above models, no signiﬁcant results
were observed (data not shown).
In the unbalanced repeated-measurement analysis of the
A1C assessed between 6 and 42 months, a clear A1C
increase with time is seen (P  0.0001), as shown in
supplementary Table A2. Neither the R61C nor the 420del
variant had a signiﬁcant genotypic effect on the mean A1C
level (P  0.75 and P  0.44, respectively). The genotype-
by-time interaction term in the model also reveals that the
two variants had no signiﬁcant effect on the rate of A1C
deterioration (P  0.38 and P  0.82, respectively).
Figure 2 is the Kaplan-Meier plot of the proportions of
patients with metformin monotherapy failure by genotype.
The Cox regression model shown in supplementary Table
A3 conﬁrms that neither the 420del nor the R61C variant
has a genotypic effect on time to monotherapy failure
(hazard ratio 0.98 [95% CI 0.82–1.18], P  0.85, and 1.08
[0.83–1.43], P  0.56, respectively). The two variants also
did not have any genotypic effect on the time to the
composite event of monotherapy failure or dose threshold
(supplementary Table A3).
DISCUSSION
In this study, we have deﬁned the response to metformin
in 1,531 patients with type 2 diabetes. Contrary to our
hypothesis, we show that two established loss-of-function
variants in SLC22A1, encoding OCT1, did not impair initial
glycemic response to metformin, the mid-term A1C con-
trol, or the rate of metformin monotherapy failure.
In our models, the A1C reduction is primarily deter-
mined by the baseline A1C. In addition, metformin re-
sponse is increased with enhanced adherence and reduced
creatinine clearance, consistent with the renal clearance
of metformin. These covariates would act to increase
availability of metformin, and this demonstrates the utility
of these models in detecting factors such as genotypes that
might alter drug availability. The nonsigniﬁcant but nega-
tive correlation of the dose with response is likely to
reﬂect a higher dose given to those who seem less likely to
respond. We show no genotypic effect of the two SLC22A1
variants tested in any model. Our study was adequately
powered to detect a clinically useful difference in met-
formin response (QUANTO, http://hydra.usc.edu/GxE/).
Assuming an additive model for the 420del genotype
(minor allele frequency [MAF] 0.20) and 1,500 subjects, the
linear regression analysis had a 90% power (0.05) to
detect a difference in A1C reduction of 0.15% per copy of
the variant allele. For the R61C genotype (MAF 0.07), the
analysis had an 80% power to detect a difference in A1C
reduction of 0.2% per copy of the variant allele.
Our study design is observational, and the results could
be prone to bias. In particular, the decision to commence
metformin and the rate of dose titration were determined
by the patients and their physicians. We had no direct
measure of intolerance. However, we have shown that
there is no variation in genotype frequency in those who
did not achieve 6 months of metformin prescriptions
compared with those who were included in the ﬁnal
cohorts; thus, any potential bias due to drug withdrawal is
minimal. A further limitation is the fact that we are unable
to measure serum metformin concentrations or to look at
change in other measures such as insulin sensitivity.
However, we believe that the study sample size of 1,531
TABLE 3
Logistic regression model of treatment to A1C target
420del R61C
OR P OR P
Genotype 0.978 0.8307 1.163 0.3554
Baseline A1C 0.748 0.0001 0.747 0.0001
Creatinine clearance 0.524 0.0003 0.523 0.0002
Average dose 0.979 0.1726 0.979 0.1690
Adherence 1.134 0.0006 1.134 0.0006
Group 0.448 0.0001 0.448 0.0001
The coefﬁcients are for the average dose per 100 mg, for creatinine
clearance per 100 ml/min, and for adherence per 10% change. The
genotypes were coded as the dosage of mutant alleles. OR, odds
ratio.
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FIG. 2. Kaplan-Meier plots showing the proportions of metformin monotherapy failure by genotypes of SLC22A1 variants 420del (A) and R61C
(B). The solid lines represent wild-type homozygote genotype (W/W), and the dotted lines represent loss-of-function allele carrier (W/M or M/M).
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effect, and we have used a similar approach successfully to
show that TCF7L2 variants affect sulfonylurea response
(13).
In the treatment-naive group, our logistic regression
found an increase of treatment success in the C-allele
carriers of an R61C variant, though only of nominal
signiﬁcance without multiple test correction. It is worth
noting that those C-allele carriers also showed a consistent
trend to better metformin response in the other A1C
outcome models: higher A1C reduction in the linear re-
gression model and lower mean A1C outcome from the
repeated-measurement analysis. This effect is in the direc-
tion opposite that in the ﬁndings of Shu et al. and, although
not deﬁnitive, would certainly suggest that our inability to
show loss of metformin response does not simply reﬂect
lack of power.
In mice, Slc22a1 was shown to be an important trans-
porter of metformin into the liver and, to a lesser extent,
into the small intestine (7,8). Subsequently, compared with
wild type, mice lacking Slc22a1 have reduced lactic acido-
sis (14) and loss of glucose reduction (10) when treated
with metformin. Shu et al. (10) have also identiﬁed a
number of rare and relatively common SLC22A1 polymor-
phisms in humans and demonstrated that 12 human,
glucose tolerant carriers of these variants showed a re-
duced efﬁcacy of metformin in lowering glucose excur-
sions in an oral glucose tolerance test compared with that
in eight control subjects. It is interesting that in a subse-
quent pharmacokinetic study, the serum metformin con-
centrations are increased in these same individuals (15),
which in mice is explained by decreased hepatic clear-
ance. In contrast to the ﬁndings of the study by Shu et al.,
in a small study of patients with type 2 diabetes deﬁned by
response or nonresponse to metformin, variation in
SLC22A1 was not consistently associated with response
(16).
The difference between our study and that of Shu et al.
could be explained by key differences in the sample
ascertainment and response models. We have studied
patients with type 2 diabetes and in a real-world setting
assessed A1C reduction in association with prolonged oral
metformin use; this compares with a more controlled
study in a few subjects with normal glucose tolerance who
are given just two doses of oral metformin and assessed by
response to oral glucose. It is generally accepted that
metformin primarily acts to suppress hepatic glucose
output (17) and, therefore, that fasting glucose may be a
better measure of efﬁcacy than the dynamic response to
oral glucose used by Shu et al. There is an ongoing
controversy over the pharmacological mechanism of met-
formin. Metformin has been shown to increase non–
insulin-mediated glucose clearance, and this effect is
responsible for as much glucose reduction as the effect on
hepatic glucose production (17). Furthermore, metformin
has also been shown to augment insulin-mediated glucose
uptake into the periphery (18) and decrease glucose
absorption from the gut (19). Given that carriers of the
loss-of-function SLC22A1 variants had increased serum
metformin concentrations (15), this may augment the
nonhepatic actions of metformin—an effect that might be
more apparent in patients with diabetes compared with
control subjects. This is an area where further study is
required.
Although in this observational study there is no appar-
ent reduction in the ability of metformin to lower A1C in
patients with type 2 diabetes carrying the R61C or 420del
loss-of-function polymorphisms in SLC22A1, this does not
rule out an effect of SLC22A1 variation on metformin
response. A more complete investigation of SLC22A1
variants would be required to fully assess the effect of the
gene on metformin response given that variants with a
more severe loss of function have been described (20).
However, we have studied the two most common loss-of-
function variants described in Europeans, and any addi-
tional known or unknown variants would be very rare. The
observational pharmacogenetic approach that we have
used in this study requires a large sample size, and the
study of rarer loss-of-function polymorphisms would lack
power in our current dataset. A more carefully controlled,
intensively phenotyped prospective study of metformin
response ideally selected by SLC22A1 genotype will have
less variation in the response phenotype and, hence,
would be better powered to detect subtle effects of
SLC22A1 variation on metformin response.
In conclusion, we have shown no clinically evident
reduction in the ability of metformin to lower A1C in
patients with type 2 diabetes with two common loss-of-
function polymorphisms in SLC22A1. A number of other
OCTs have recently been implicated in the transport of
metformin: SLC22A2 (OCT2) (9,21), MATE (22), and
PMAT (23). These are clearly of interest in the regulation
of metformin response; in particular, SLC22A2 is involved
in renal excretion of metformin and has been shown to
have a greater afﬁnity for metformin than SLC22A1 (9). In
addition to a further study of SLC22A1, a detailed phar-
macogenetic study of these metformin transporters is also
required.
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